Kiniksa Pharmaceuticals, Ltd. (KNSA) P/E Ratio History
Historical price-to-earnings valuation from 2022 to 2026
Loading P/E history...
KNSA Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Kiniksa Pharmaceuticals, Ltd. (KNSA) trades at a price-to-earnings ratio of 75.9x, with a stock price of $56.93 and trailing twelve-month earnings per share of $0.89.
The current P/E is 36% below its 5-year average of 118.3x. Over the past five years, KNSA's P/E has ranged from a low of 3.9x to a high of 691.8x, placing the current valuation at the 60th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, KNSA trades at a 240% premium to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, KNSA commands a significant premium over the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our KNSA DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
KNSA P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 6.9Lowest | 0.67 | +817%Best | |
| $30B | 22.8 | 0.56Best | +5% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
KNSA Historical P/E Data (2022–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | $48.15 | $0.91 | 52.9x | -55% | |
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $41.25 | $0.75 | 55.0x | -54% |
| FY2025 Q3 | $38.83 | $0.45 | 86.3x | -27% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $27.67 | $0.04 | 691.8x | +485% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $19.73 | $0.11 | 179.4x | +52% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $17.54 | $0.18 | 97.4x | -18% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $14.08 | $3.27 | 4.3x | -96% |
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $10.76 | $2.77 | 3.9x | -97% |
| FY2022 Q4 | Sat Dec 31 2022 00:00:00 GM | $14.98 | $2.59 | 5.8x | -95% |
| FY2022 Q3 | Fri Sep 30 2022 00:00:00 GM | $12.84 | $2.00 | 6.4x | -95% |
Average P/E for displayed period: 118.3x
See KNSA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs KNSA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare KNSA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonKNSA — Frequently Asked Questions
Quick answers to the most common questions about buying KNSA stock.
Is KNSA stock overvalued or undervalued?
KNSA trades at 75.9x P/E, below its 5-year average of 118.3x. At the 60th percentile of historical range, the stock is priced at a discount to its own history.
How does KNSA's valuation compare to peers?
Kiniksa Pharmaceuticals, Ltd. P/E of 75.9x compares to sector median of 22.3x. The premium reflects expected growth above peers.
What is KNSA's PEG ratio?
KNSA PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2022-2026.